MS Pharmacy Practice Act; extend repealer on.
SB 2694 is a Mississippi pharmacy “sunset” bill that extends the repeal date of the Mississippi Pharmacy Practice Act from July 1, 2025 to July 1, 2029. It also extends the repeal date for the provision allowing the State Board of Pharmacy to discipline licensees for violations of the Patient’s Right to Informed Health Care Choices Act. In addition to those date changes, the bill makes minor nonsubstantive grammatical corrections in several sections and brings forward the remaining sections of the Pharmacy Practice Act for possible future amendment.
Substantively, the bill leaves most of the pharmacy regulatory framework in place and reaffirms the State Board of Pharmacy’s authority over pharmacist licensure, technician registration, discipline, permits for pharmacies and wholesalers, nonresident pharmacies, home medical equipment suppliers, and the Prescription Monitoring Program. It also preserves existing rules on criminal background checks, continuing education, emergency dispensing, generic and biological product substitution, labeling, pseudoephedrine/ephedrine sales controls, charitable community pharmacy immunity, and manufacturer drug return obligations. The bill takes effect June 30, 2025.
The bill primarily affects Mississippi Code Title 73, Chapter 21 by extending the life of the Mississippi Pharmacy Practice Act and related disciplinary authority, preventing those provisions from expiring in 2025. Because the act is brought forward rather than rewritten, the practical effect is to keep the current licensing, permitting, inspection, enforcement, and prescription-monitoring statutes operative while preserving them for later amendment. It does not create a new regulatory scheme, but it maintains the State Board of Pharmacy’s existing oversight of pharmacists, pharmacies, technicians, wholesalers, nonresident pharmacies, and related entities.
The available record shows no committee transcript, recorded debate, or vote history, so there is no documented opposition or support beyond the bill’s introduction. Based on the bill’s content and title, it appears to be a routine continuation measure designed to avoid a statutory sunset rather than a controversial policy change. The absence of recorded votes or discussion suggests the bill was treated as a technical or housekeeping measure.
No specific points of contention are documented in the provided materials. If any concerns were raised, they are not reflected in the available transcripts or voting history. The only potentially sensitive provisions are the continued disciplinary authority tied to informed health care choices, the Board’s broad enforcement powers, and the ongoing controls on controlled substances and pseudoephedrine sales, but the record provided does not show any active dispute over them.